Frontier IP Group plc (AIM: FIPP), a specialist in commercialising intellectual property, has announced that its portfolio company The Vaccine Group Limited (TVG) and the UK government's Animal and Plant Health Agency (APHA) have been awarded a £500,000 grant to advance bovine respiratory syncytial virus (BRSV) vaccine research. The funding comes through Defra's Farming Innovation Programme, delivered in partnership with Innovate UK, and builds on positive trial results announced in November 2025. Frontier IP holds a 16.95 per cent equity stake in TVG, a spin-out from the University of Plymouth, making the grant a material development for the Group's portfolio.

Key Points

  • Frontier IP Group plc (AIM: FIPP) is a specialist intellectual property commercialisation group with a 16.95% equity stake in The Vaccine Group Limited
  • TVG and APHA have been awarded a £500,000 Innovate UK grant through Defra's Farming Innovation Programme to develop a BRSV cattle vaccine
  • BRSV costs British farmers an estimated £54 million annually, with a global cost estimated at up to £5.6 billion, according to The Pirbright Institute
  • Investors may watch for further clinical milestones, minimum-dose study results, and progress on TVG's broader herpesvirus-based vaccine platform

£500,000 Defra and Innovate UK Grant to Fund TVG's BRSV Minimum-Dose and Single-Vaccination Study

The newly awarded £500,000 will fund a study designed to determine the minimum vaccine dose required to provide effective protection against BRSV and to assess whether that protection can be achieved through a single vaccination. This builds directly on trials run by APHA using two TVG vaccine candidates, the results of which were announced in November 2025 and described in the announcement as an outstanding success. Specialist animal health and veterinary group Synergy Farm Health will also participate in the project, examining the incidence, treatment, and associated antibiotic use of bovine respiratory disease across English cattle herds to place the research in a practical farming context.

BRSV's Economic Burden on British and Global Cattle Farming Underlines Commercial Opportunity for TVG

BRSV is a highly contagious disease and a leading cause of bovine respiratory disease in cattle globally. The Pirbright Institute has estimated its annual cost to British farmers at £54 million. The global figure, based on assumptions that 25 per cent of an estimated 450 million annual bovine respiratory cases are attributable to BRSV at an average cost of £50 per cow across a global cattle population of 1.5 billion, is conservatively estimated at £5.6 billion. This scale of economic damage positions an effective vaccine as a potentially significant commercial product, and Dr Jeremy Salt, TVG's Chief Executive, stated in the announcement that he is optimistic about the commercial prospects of the BRSV vaccines.

TVG's Herpesvirus Platform Validated Across Viral and Bacterial Diseases in Multiple Animal Species

Beyond the BRSV programme, the announcement highlights that TVG has also reported strong results for a pig vaccine candidate targeting Streptococcus suis, a zoonotic bacterial disease capable of causing meningitis and sepsis in humans. The dual success of these trials indicates that TVG's novel herpesvirus-based vaccine platform demonstrates efficacy against both viral and bacterial diseases and across different animal species, which may broaden the platform's future commercial applications. Frontier IP Chief Executive Neil Crabb described the continued Innovate UK funding and APHA support as a strong validation of the underlying technology and its commercial potential.

Frontier IP's 16.95% Stake in TVG and Its IP Commercialisation Model

Frontier IP operates by identifying strong intellectual property and accelerating its development through commercialisation services, taking equity stakes and licence income in spin-out companies such as TVG. The Group's 16.95 per cent equity stake in TVG, a University of Plymouth spin-out, means that progress in TVG's clinical and commercial pipeline is directly relevant to Frontier IP's portfolio valuation. The involvement of established partners including APHA, The Pirbright Institute, and Synergy Farm Health reflects Frontier IP's stated strategy of engaging relevant industry partners at an early stage to ensure technology meets real-world demands.